尿囊素铝对比替普瑞酮治疗胃炎及消化性溃疡的临床应用研究

Clinical Application of Aldioxa Compared with Teprenone in the Treatment of Gastritis and Peptic Ulcer

目的研究尿囊素铝对比替普瑞酮治疗胃炎及消化性溃疡的临床应用效果。方法该次研究选取的研究对象为2014年2月—2017年1月期间在该院进行治疗的胃炎及消化性溃疡患者,将68例患者计算机随机分为2组,每组34例。其中,一组患者实施替普瑞酮治疗(对照组),另一组采用尿囊素铝治疗(观察组)。对比两组胃炎及消化性溃疡患者的临床效果、不良反应发生率、炎症改善情况以及复发率。结果观察组胃炎及消化性溃疡患者的临床总有效率(94.12%、88.24%)高于对照组患者(P<0.05),两组患者的不良反应发生率数据进行比较相差不大(P>0.05),复发率(5.88%)低于对照组(P<0.05)。炎症改善程度优于对照组(P<0.05)。结论尿囊素铝应用在胃炎及消化性溃疡患者的治疗中效果比替普瑞酮更优越,适合推广于临床中。

Objective This paper tries to study the clinical effect of aldioxa compared with teprenone in the treatment of gastritis and peptic ulcer. Methods 68 patients with gastritis and peptic ulcer treated in this hospital from February2014 to January 2017 were randomly divided into two groups, with 34 cases in each group. The control group adopted teprenone treatment, the observation group adopted aldioxa treatment, the clinical efficiency, adverse incidence, improvement condition and recurrence rate of these patients in both groups were compared and analyzed. Results The total effective rate of patients with gastritis and peptic ulcer were 94.12% and 88.24%, higher than that in the control group（P0.05）. There was no significant difference in the incidence of adverse events between the two groups（P0.05）.The recurrence rate in the observation group was 5.88% lower than that of the control group（P0.05）. The degree of inflammation improvement in the observation group was better than that of the control group（P0.05）. Conclusion The effect of aldioxa in the treatment of gastritis and peptic ulcer is superior to that of teprenone and is suitable for clinical application.